Chronic administration of peroxisome proliferators to mice and rats results in hepatomegaly and ultimately carcinogenesis. The mechanism underlying the carcinogenic effect of nongenotoxic peroxisome proliferators is not well understood. To determine whether nongenotoxic carcinogenesis is receptor mediated, we evaluated the effect of the prototypical peroxisome proliferator Wy-14,643 on replicative DNA synthesis and carcinogenesis in the PPARα-null mouse line. Male mice (F 4 , Sv/129 ter) of both genotypes (ϩ/ϩ) and (-/-) were fed either a control diet or one containing 0.1% Wy-14,643 for either 1 week, 5 weeks, or 11 months. Wild-type mice fed the Wy-14,643 diet for 1 or 5 weeks showed increased hepatic labeling by bromodeoxyuridine (BrDU) compared to untreated controls. In contrast, there was no increase in hepatic BrDU labeling index in (-/-) mice fed the Wy-14,643 diet for the same time periods compared to controls. After 11 months, 100% of the (ϩ/ ϩ) mice fed the Wy-14,643 diet had multiple hepatocellular neoplasms, including adenomas and carcinomas, while the (-/-) mice fed the Wy-14,643 diet were unaffected. This work demonstrates that the effects of Wy-14,643 on replicative DNA synthesis and hepatocarcinogenesis are mediated by PPARα.
Introduction
Peroxisome proliferators are a diverse class of compounds that include naturally occurring steroids and fatty acids as well as synthetic compounds ranging from plasticizers (e.g. di- [2-ethylhexyl] phthalate) to hypolipidemic drugs (e.g. clofibrate and Wy-14,643) (1) (2) (3) (4) (5) . Administration of peroxisome proliferators to mice and rats results in an increase in the number and size of peroxisomes and increased expression of genes encoding peroxisomal lipid metabolizing enzymes. Peroxisome proliferators cause an increase in peroxisomal enzymes that catalyze β-oxidation of fatty acids as well as an increase in microsomal enzymes that catalyze ω-oxidation of long chain, polyunsaturated fatty acids. Both of these changes in enzymatic activity occur through increases in gene transcription and are mediated by the peroxisome proliferator-activated receptor-α (PPARα*). PPARα is a member of the nuclear receptor superfamily and in conjunction with retinoid X receptor (RXR), binds to peroxisome proliferator responsive elements (PPRE) *Abbreviations: PPARα, proliferator-activated receptor-α; RXR, retinoid X receptor; PPRE, peroxisome proliferator responsive elements; PBF, phosphatebuffered formalin; BrDU, bromodeoxyuridine; PBS, phosphate-buffered saline.
© Oxford University Press 2029 to activate gene expression. Definitive proof that PPARα mediates peroxisome proliferation and altered gene expression was provided by the PPARα-null mouse that was found to be refractive to peroxisome proliferators (6) .
Chronic administration of peroxisome proliferators to rats and mice results in hepatocellular carcinomas (5, (7) (8) (9) (10) . The mechanisms underlying the carcinogenesis of peroxisome proliferators, which are neither DNA-reactive nor mutagenic, have not been delineated. Two non-exclusive mechanisms have been proposed. Peroxisome proliferation is associated with an increase in H 2 O 2 levels, due to increased peroxisomal β-oxidation, that is not compensated for by higher catalase activity (11) . H 2 O 2 can cause DNA damage through formation of adducts such as 8-hydroxyguanine or strand breaks. Peroxisome proliferators also cause alterations in cell cycle control which might contribute to the underlying mechanism of peroxisome proliferator-induced carcinogenesis including changes in apoptosis (12) and alterations in cell division in liver (13, 14) .
There are notable species differences in response to peroxisome proliferators. Humans and primates appear to be resistant to peroxisome proliferation (3, 15, 16) . Humans treated with hypolipidemic drugs such as gemfibrozil for many years have shown no evidence of elevated peroxisomes or other histological changes found in rodents (16) . There is also no epidemiological evidence for increased liver cancer in these patients. While humans do contain a functional PPARα, the mechanism of their resistance to peroxisome proliferation is not known.
In this work, we evaluated the effect of a prototypical peroxisome proliferator, Wy-14,643 on replicative DNA synthesis and carcinogenesis in mice deficient for PPARα to determine if these events are mediated by PPARα.
Materials and methods

Diet
[4-Chloro-6-(2,3-xylidino)-pyrimidynylthio]acetic acid (Wy-14,643) was purchased commercially from ChemSyn Science Laboratories (Lenexa, KS). Pelleted mouse chow was prepared containing either 0.0 (control) or 0.1% Wy-14,643 (Bioserv, Frenchtown, NJ) and provided to mice ad libitum. The rate and route of administration were consistent with a previous study demonstrating the carcinogenicity of Wy-14,643 in acatalsemic mice (10).
Short-term experiments
Seven-to eight-week-old, PPARα (ϩ/ϩ) or (-/-) male mice on an Sv/129 background (F 4 generation), were housed 4-5 animals per cage in a temperature-and light controlled environment (T ϭ 25°C, 12 h light/dark cycle). To assess replicative DNA synthesis in response to peroxisome proliferator administration, mice were fed Wy-14,643 for 1 week or 5 weeks. For the 1-week experimental period, on the morning of diet initiation, mice were weighed and then anesthetized with 2.5% avertin (100% avertin ϭ 1 g tribromoethyl alcohol/ml tertiary amyl alcohol) and an osmotic pump (Alzet model 2001, 1 µl/h; Alza Corporation, Palo Alto, CA) was implanted subcutaneously containing 200 µl of 16 mg/ml BrDU (Sigma Chemical Co., St Louis, MO). Mice were placed on heating pads until they recovered from anesthesia and then returned to their cage for the remainder of the experiment. After 1 week of being fed their respective diet, mice were weighed and then euthanized by overexposure to carbon dioxide. Livers were removed and weighed. Sections (~2-3 mm) from both the left and median lobes were obtained and fixed in 10% phosphate-buffered formalin (PBF) (Fisher Scient- ific, Fair Lawn, NJ). Sections from the duodenum were also obtained and fixed in PBF. The duodenum sample was used to verify uniform flow of bromodeoxyuridine (BrDU) up to the time the animals were euthanized.
For the 5-week treatment period, mice from both genotypes were weighed and fed either the control or the Wy-14,643 diet for 4 weeks. At the end of this 4-week period, mice were anesthetized and osmotic pumps implanted as described above. Mice were fed their respective diets for one more week after surgery and tissues collected as described above.
Long-term experiment
Seven-to eight-week-old, PPARα (ϩ/ϩ) or (-/-) male mice on an Sv/129 background (F 4 generation), were housed as described above. Mice from both genotypes were fed either the control or the Wy-14,643 diet for 11 months unless morbidity necessitated earlier euthanasia. Monthly body wts were measured and at the end of the 11-month feeding period, livers were removed, rinsed in phosphate-buffered saline (PBS), and weighed. Gross lesions were sampled for histological examination (see below).
BrDU immunohistochemistry
Tissue sections were fixed in 10% PBF for at least 1 week, transferred to 70% ethanol, and then processed to paraffin blocks. Sections (5 µm) were cut with a rotary microtome, mounted on Probe-On Plus a slides (Fisher Scientific, Pittsburgh, PA) and allowed to air dry. Slides were treated with xylene for 3 min (3X) followed by two 1-min incubations in 100% ethanol and finally 1 min in 95% ethanol. After digestion in 0.01% trypsin in 50 mM Tris-HCl, DNA was denatured with 2 N HCl at 37°C. Immunostaining was performed with a monoclonal antibody (Caltag Laboratories, San Francisco, CA) against BrDU diluted 1:1500 in 0.5% BSA in PBS. Immunohistochemical detection was performed using a streptavidin alkaline phosphatase method (Vector Laboratories, Burlingame, CA) followed by staining with Fast Red Chromogen 2030 (Biomeda Corporation, Foster City, CA). Slides were counterstained with hematoxylin. For determination of the labeling index, slides stained for BrDU were examined at 200X. Stained and unstained hepatocyte nuclei were counted at randomly generated coordinates that were found within an eyepiece reticle field (1ϫ1 cm). Labeling index was determined by counting at least 1500 nuclei per slide, and calculated as 100% ϫ number stained/(number stained ϩ number unstained).
Tumor histology
Each lobe of the liver was examined for the presence of gross lesions. For each mass, the diameter was estimated and location recorded, and then a representative sample was placed in PBF. Paraffin sections were prepared, stained with hematoxylin and eosin, and examined for the presence of hepatocellular proliferative lesions (carcinoma, adenoma, or focus of cellular alteration) per established criteria (17) . In mice lacking masses, representative sections of left and median lobes were similarly prepared and evaluated.
Results
Short-term experiments
Wild-type and PPARα null mice were compared during feeding of Wy-14,643. There was no difference in terminal body wt between any of the four treatment groups after 1 week (Table  I) . However, body wt change (final body wt -initial body wt) was significantly lower in (ϩ/ϩ) mice fed the Wy-14,643 diet for 1 week compared to (ϩ/ϩ) control mice and both groups of (-/-) mice (Table I ). In the (ϩ/ϩ) mice fed the Wy-14,643 diet for 1 week, mean relative liver wt (g liver/Kg body wt) was significantly higher compared to (ϩ/ϩ) control mice (Table I ). In contrast, relative mean liver wt in both the Wy-14,643-fed and control (-/-) mice was not different from control (ϩ/ϩ) mice (Table I ). The increase in liver wt in (ϩ/ϩ) mice fed the Wy-14,643 diet for 1 week was accompanied by a significantly higher BrDU labeling index in liver tissue sections compared to (ϩ/ϩ) controls ( Figure 1A ). Hepatocellular BrDU labeling index was not increased by Wy-14,643 in (-/-) mice ( Figure 1A ). It should be pointed out that the relatively higher BrDU labeling index seen in the control (-/-) mice is likely due to the fact that these mice were 7 weeks of age versus 8 weeks for the other groups at this time point and the higher growth rate of the livers might reflect normal postnatal development.
Terminal body wt was significantly lower in (ϩ/ϩ) mice fed the Wy-14,643 diet for 5 weeks compared to untreated (ϩ/ϩ) and both treatment groups of (-/-) mice (Table I) . This difference was also reflected in the total wt change between initial body wt and final body wt (Table I ). As observed after 1 week, only those (ϩ/ϩ) mice fed the Wy-14,643 diet had significantly higher relative liver wts compared to untreated control (ϩ/ϩ) mice (Table I) . Similarly, there was no difference in relative liver wt between (-/-) mice fed either the Wy-14,643 or control diet for 5 weeks (Table I) . Relative liver wts in control fed (-/-) and (ϩ/ϩ) mice were similar. The increase in liver wt observed in (ϩ/ϩ) mice fed the Wy-14,643 diet for 5 weeks was also associated with a higher hepatic BrDU labeling index compared to control fed (ϩ/ϩ) mice ( Figure  1B ). There was no difference in liver BrDU labeling index in the (-/-) mice fed the Wy-14,643 for 5 weeks compared to controls ( Figure 1B) .
Long-term experiment
Body wt was significantly lower shortly after the onset of feeding the Wy-14,643 diet in (ϩ/ϩ) mice compared to controls, and this difference was not observed in Wy-14,643-fed (-/-) mice (data not shown). Further, this difference persisted in only the Wy-14,643-treated (ϩ/ϩ) mice until the end of the experiment (Table I) . Out of the nine mice in the Wy-14,643-treated (ϩ/ϩ) group, three mice died and were not evaluated further while one mouse was euthanized due to morbidity prior to the end of the experiment. No other mice died in any of the remaining experimental groups. At the end of the 11-month feeding period, mean relative liver wt was significantly higher in the Wy-14,643-treated (ϩ/ϩ) mice compared to controls (Table I) . No difference in mean relative liver wt was observed in the (-/-) mice fed the Wy-14,643 diet compared to controls ( Table I ). All of the (ϩ/ϩ) mice fed the Wy-14,643 diet had multiple, grossly visible nodules, up to~11 mm in diameter that were randomly distributed among the liver lobes. Results of the microscopic evaluation of all lesions Ͼ3 mm in diameter are presented in Table II . Hepatocellular adenomas and in some cases, carcinomas, were apparent in sections of the gross lesions from the Wy-14,643-treated (ϩ/ϩ) mice (Figure 2) . Interestingly, none of the Wy-14,643-treated (-/-) mice had gross or microscopic evidence of hepatic neoplasia (Figure 2 ). Microscopic evaluation of liver sections from these mice also failed to reveal any foci of cellular alteration, lesions that represent precursors of neoplasia.
Discussion
Short-term and long-term Wy-14,643 feeding (1 and 5 weeks and 11 months) resulted in hepatomegaly in wild-type mice. Interestingly, relative liver wt increased with the duration of treatment showing a progressive, yet sustained effect. Similarly, an increase in hepatic nuclear BrDU labeling index was observed in Wy-14,643-fed wild-type mice after 1 and 5 weeks of treatment. These observations are consistent with other 2032 reports of increased measures of DNA replicative synthesis in animals exposed to Wy-14,643 (13, 14, 21, 22) . Since hepatomegaly and the increase in hepatic nuclear BrDU labeling due to Wy-14,643-feeding were not observed in the PPARα null mouse, it appears that Wy-14,643-induced hyperplasia and the increase in DNA replicative synthesis are mediated by PPARα.
Prolonged oral exposure of mice and rats to Wy-14,643 and other peroxisome proliferators typically results in hepatocellular neoplasia (5, (7) (8) (9) (10) . In the present study, all of the PPARα wild-type mice fed Wy-14,643 had multiple hepatocellular neoplasms, including some carcinomas, after only 11 months of exposure. In contrast, PPARα-null mice uniformly lacked any evidence of neoplastic or preneoplastic lesions at the gross and microscopic level. This observation represents the first conclusive evidence that PPARα is required for the carcinogenic response to a peroxisome proliferator. Since Wy-14,643 is a reasonable prototype for a variety of chemicals that cause peroxisome proliferation, hyperplasia, and neoplasia in liver, the activation of PPARα is likely a general feature of the mechanism by which several pharmaceutical and industrial chemicals are hepatocarcinogenic in rodents.
The significance of these results for human populations is not clear since humans do not typically respond to PPARα activators by peroxisome proliferation (15, 16) . This may be the result of lower hepatic expression of PPARα in humans compared to rodent species (20) . Despite this disparity, these results clearly demonstrate that PPARα mediates carcinogenesis of Wy-14,643 in mice.
These results do not provide evidence to identify the underlying mechanism(s) of peroxisome proliferator-induced hepatocarcinogenesis. However, the changes in replicative DNA synthesis we observed support the hypothesis that alterations in cell cycle kinetics contribute to this effect. Alternatively, the lack of peroxisome proliferation and altered gene expression of peroxisomal and microsomal proteins (6) that typically result from peroxisome proliferator treatment could also contribute to the carcinogenesis of peroxisome proliferators. Nevertheless, our results clearly demonstrate that PPARα is required for the increase in hepatic replicative DNA synthesis in response to the peroxisome proliferator Wy-14,643 and that the carcinogenesis resulting from prolonged exposure to Wy-14,643 is mediated by PPARα as well.
